FDA Drug recall D-1214-2018
Morphine Sulfate Extended-Release Tablets, 30 mg, 100-count bottle, Rx only, Manufactured by: Novel Laboratories, Inc
- FDA Drug
- Class III
- terminated
- Published 2018-09-26
On 2018-09-26 the FDA classified a Class III recall of Morphine Sulfate Extended-Release Tablets, 30 mg, 100-count bottle, Rx only, Manufactured by: Novel Laboratories, Inc by Lupin Somerset, citing failed Impurities/Degradation Specifications: Morphine Sulfate Extended Release Tablets are being recalled due to out of Specification Result noticed for Morphinone Sulfate impuri….
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1214-2018 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2018-08-23 |
| Published | 2018-09-26 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Lupin Somerset |
| Distribution | US |
Product
Morphine Sulfate Extended-Release Tablets, 30 mg, 100-count bottle, Rx only, Manufactured by: Novel Laboratories, Inc. Somerset, NJ 08873, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202, NDC 43386-541-01
Reason
Failed Impurities/Degradation Specifications: Morphine Sulfate Extended Release Tablets are being recalled due to out of Specification Result noticed for Morphinone Sulfate impurity during 3 month stability analysis and during retain testing.
Identifiers
| ndc | 43386-540-01 |
|---|---|
| ndc | 43386-540-05 |
| ndc | 43386-541-01 |
| ndc | 43386-541-05 |
| ndc | 43386-542-01 |
| ndc | 43386-542-05 |
| ndc | 43386-543-01 |
| ndc | 43386-543-05 |
| ndc | 43386-544-01 |
| ndc | 43386-544-05 |
| code_info | Lot# S800232, Exp 2/20 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1214-2018%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.